Windlas Biotech Ltd - 543329 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Recording Of Conference Call
Windlas Biotech informed that the audio recording of its Investors/Analyst conference call, held on May 18, 2026, for Q4 FY26 financial results, is now available on its website. The transcript will be shared with exchanges and uploaded in due course.
May 22 2026 16:33:33
Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Windlas Biotech reported Q4 FY26 revenue increased 18% YoY to Rs.238 crore, with net profit up 39% YoY to Rs.23 crore. Full-year FY26 revenue rose 19% to Rs.904 crore, with net profit up 31% to Rs.83 crore. The board proposed a dividend of Rs.6.30 per share for FY26.
May 21 2026 17:37:54
Windlas Biotech Ltd - 543329 - Board Meeting Outcome for Outcome Of The Board Meeting
Windlas Biotech's board approved Q4 & FY26 cons. financial results. Q4 cons. revenue increased by 17.66% YoY to ₹238.50 cr, while Q4 net profit was ₹15.99 cr. The company also recommended a final dividend of ₹6.30 per share for FY26 and completed a ₹47 cr share buyback.
May 21 2026 16:33:23
Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Closure of Buy Back
Windlas Biotech completed the buyback of 4.7 lakh equity shares at Rs.1,000 per share, totaling Rs.47 crore. The extinguishment process was finalized on May 18, 2026, reducing the company's equity capital.
May 18 2026 17:55:37
Windlas Biotech Ltd - 543329 - Submission Of Post Buyback Public Announcement
Windlas Biotech completed the buyback of 4.70 lakh equity shares. The shares were acquired at a price of Rs. 1,000 each, making the total buyback value Rs. 47 crore. This move indicates the company's confidence.
May 16 2026 12:39:55
Windlas Biotech Ltd - 543329 - Board Meeting Intimation for Notice Of The Board Meeting Scheduled To Be Held On Thursday, May 21, 2026
Windlas Biotech board will convene on May 21, 2026, to consider and approve its audited full FY26 financial results. They will also discuss a potential dividend recommendation for the financial year ended March 31, 2026.
May 15 2026 14:13:06
Windlas Biotech Ltd - 543329 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
ICICI Prudential Mutual Fund has reduced its stake in Windlas Biotech by 2.63%, bringing its total holding down to 4.33%. This stake reduction occurred through open market sales between July 2024 and May 2026.
May 15 2026 11:04:04
Read More